To include your compound in the COVID-19 Resource Center, submit it here.

Morphiex’s antisense take on CD47 aims for more than eating

Morphiex enters the CD47 race with an antisense approach that activates immunity

Morphiex is breaking from the CD47 pack by undercutting the target’s expression on both tumor and immune cells instead of just blocking tumors’ “don’t eat me” signals via SIRPA. The company believes its antisense approach could unleash T cell and NK cell activity, and avoid the red blood cell toxicity that has loomed over the CD47 space.

“Everyone else is blocking it, but we’re actually reducing

Read the full 655 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE